Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva
Executive Summary
Hemophilia and immuno-oncology will be in the spotlight as earnings season continues into February. Will Bristol be a buyer or an acquisition target? How will Sanofi fare with its new acquisitions? And how will Teva and GSK fare as they face generics for top brands?